Literature DB >> 28419269

Dual-Genotype Diffuse Low-Grade Glioma: Is It Really Time to Abandon Oligoastrocytoma As a Distinct Entity?

Valeria Barresi1, Simona Lionti1, Laura Valori1, Giovanna Gallina1, Maria Caffo1, Sabrina Rossi1.   

Abstract

We report a unique case of dual-genotype oligoastrocytoma characterized by IDH2 gene mutation. The tumor was resected from the temporal lobe of a 25-year-old man. At histological examination with hematoxylin and eosin stain, it showed distinct oligodendroglial and astrocytic areas. The former retained alpha-thalassaemia/mental retardation X-linked (ATRX) immuno-expression and had absent staining for p53, while the latter had ATRX loss and p53 over-expression. Molecular analyses were separately assessed in the 2 tumor components. Gene sequencing disclosed IDH2 mutation in both, whereas oligodendroglial, but not astrocytic areas, had 1p/19q codeletion and telomerase reverse transcriptase promoter mutation. Distinction of dual-genotype oligoastrocytoma from oligodendroglioma and astrocytoma might be clinically relevant for prognosis and therapy. Because most studies that investigated the molecular phenotype of oligoastrocytomas have focused on IDH1 R132H mutated cases, we suggest further analyses on diffuse gliomas with heterogeneous (astrocytic and oligodendroglial) morphology before oligoastrocytoma is dismissed as a distinct nosological entity.
© 2017 American Association of Neuropathologists, Inc. All rights reserved.

Entities:  

Keywords:  1p/19q Codeletion; ATRX; IDH; Oligoastrocytoma; TERT

Mesh:

Substances:

Year:  2017        PMID: 28419269     DOI: 10.1093/jnen/nlx024

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  7 in total

Review 1.  Evolving Insights into the Molecular Neuropathology of Diffuse Gliomas in Adults.

Authors:  Floris P Barthel; Kevin C Johnson; Pieter Wesseling; Roel G W Verhaak
Journal:  Neurol Clin       Date:  2018-08       Impact factor: 3.806

2.  Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas.

Authors:  Josie Hayes; Yao Yu; Llewellyn E Jalbert; Tali Mazor; Lindsey E Jones; Matthew D Wood; Kyle M Walsh; Henrik Bengtsson; Chibo Hong; Stefan Oberndorfer; Thomas Roetzer; Ivan V Smirnov; Jennifer L Clarke; Manish K Aghi; Susan M Chang; Sarah J Nelson; Adelheid Woehrer; Joanna J Phillips; David A Solomon; Joseph F Costello
Journal:  Neuro Oncol       Date:  2018-04-09       Impact factor: 12.300

Review 3.  Molecular pathology of tumors of the central nervous system.

Authors:  B W Kristensen; L P Priesterbach-Ackley; J K Petersen; P Wesseling
Journal:  Ann Oncol       Date:  2019-08-01       Impact factor: 32.976

4.  True anaplastic oligoastrocytoma with dual genotype: illustrative case.

Authors:  Reina Mizuno; Taku Homma; Jun-Ichi Adachi; Kazuhiko Mishima; Tomonari Suzuki; Mitsuaki Shirahata; Ryo Nishikawa; Sasaki Atushi
Journal:  J Neurosurg Case Lessons       Date:  2022-07-18

5.  Recurrent oligodendroglioma with changed 1p/19q status.

Authors:  Valeria Barresi; Andrea Mafficini; Martina Calicchia; Maria Liliana Piredda; Angelo Musumeci; Claudio Ghimenton; Aldo Scarpa
Journal:  Neuropathology       Date:  2022-02-10       Impact factor: 2.076

6.  Recurrent Glioma With Lineage Conversion From Oligodendroglioma to Astrocytoma in Two Cases.

Authors:  Jo-Heon Kim; Woo-Youl Jang; Tae-Young Jung; Shin Jung; Kyung-Keun Kim; Hyung-Seok Kim; Eun-Hee Kim; Min-Cheol Lee; Kyung-Sub Moon; Kyung-Hwa Lee
Journal:  Front Oncol       Date:  2019-08-27       Impact factor: 6.244

7.  IDH-wild type glioblastomas featuring at least 30% giant cells are characterized by frequent RB1 and NF1 alterations and hypermutation.

Authors:  Valeria Barresi; Michele Simbolo; Andrea Mafficini; Maurizio Martini; Martina Calicchia; Maria Liliana Piredda; Chiara Ciaparrone; Giada Bonizzato; Serena Ammendola; Maria Caffo; Giampietro Pinna; Francesco Sala; Rita Teresa Lawlor; Claudio Ghimenton; Aldo Scarpa
Journal:  Acta Neuropathol Commun       Date:  2021-12-24       Impact factor: 7.801

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.